🎉 M&A multiples are live!
Check it out!

Capricor Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Capricor Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Capricor Therapeutics Overview

About Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.


Founded

2005

HQ

United States of America
Employees

160

Website

capricor.com

Financials

LTM Revenue $36.4M

LTM EBITDA -$28.5M

EV

$279M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Capricor Therapeutics Financials

Capricor Therapeutics has a last 12-month revenue of $36.4M and a last 12-month EBITDA of -$28.5M.

In the most recent fiscal year, Capricor Therapeutics achieved revenue of $22.3M and an EBITDA of -$41.1M.

Capricor Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Capricor Therapeutics valuation multiples based on analyst estimates

Capricor Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $25.2M $22.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$23.0M -$41.1M XXX XXX XXX
EBITDA Margin -91% -185% XXX XXX XXX
Net Profit -$29.0M -$22.3M XXX XXX XXX
Net Margin -115% -100% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Capricor Therapeutics Stock Performance

As of April 15, 2025, Capricor Therapeutics's stock price is $9.

Capricor Therapeutics has current market cap of $429M, and EV of $279M.

See Capricor Therapeutics trading valuation data

Capricor Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$279M $429M XXX XXX XXX XXX $-0.93

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Capricor Therapeutics Valuation Multiples

As of April 15, 2025, Capricor Therapeutics has market cap of $429M and EV of $279M.

Capricor Therapeutics's trades at 7.7x LTM EV/Revenue multiple, and -9.8x LTM EBITDA.

Analysts estimate Capricor Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Capricor Therapeutics and 10K+ public comps

Capricor Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $279M XXX XXX XXX
EV/Revenue 12.5x XXX XXX XXX
EV/EBITDA -6.8x XXX XXX XXX
P/E -10.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -6.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Capricor Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Capricor Therapeutics Valuation Multiples

Capricor Therapeutics's NTM/LTM revenue growth is 128%

Capricor Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Over next 12 months, Capricor Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Capricor Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Capricor Therapeutics and other 10K+ public comps

Capricor Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -12% XXX XXX XXX XXX
EBITDA Margin -185% XXX XXX XXX XXX
EBITDA Growth 79% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -57% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 64% XXX XXX XXX XXX
R&D Expenses to Revenue 224% XXX XXX XXX XXX
Opex to Revenue 291% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Capricor Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Capricor Therapeutics M&A and Investment Activity

Capricor Therapeutics acquired  XXX companies to date.

Last acquisition by Capricor Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Capricor Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Capricor Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Capricor Therapeutics

When was Capricor Therapeutics founded? Capricor Therapeutics was founded in 2005.
Where is Capricor Therapeutics headquartered? Capricor Therapeutics is headquartered in United States of America.
How many employees does Capricor Therapeutics have? As of today, Capricor Therapeutics has 160 employees.
Who is the CEO of Capricor Therapeutics? Capricor Therapeutics's CEO is Dr. Linda Marban, PhD.
Is Capricor Therapeutics publicy listed? Yes, Capricor Therapeutics is a public company listed on NAS.
What is the stock symbol of Capricor Therapeutics? Capricor Therapeutics trades under CAPR ticker.
When did Capricor Therapeutics go public? Capricor Therapeutics went public in 2007.
Who are competitors of Capricor Therapeutics? Similar companies to Capricor Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Capricor Therapeutics? Capricor Therapeutics's current market cap is $429M
What is the current revenue of Capricor Therapeutics? Capricor Therapeutics's last 12-month revenue is $36.4M.
What is the current EBITDA of Capricor Therapeutics? Capricor Therapeutics's last 12-month EBITDA is -$28.5M.
What is the current EV/Revenue multiple of Capricor Therapeutics? Current revenue multiple of Capricor Therapeutics is 7.7x.
What is the current EV/EBITDA multiple of Capricor Therapeutics? Current EBITDA multiple of Capricor Therapeutics is -9.8x.
What is the current revenue growth of Capricor Therapeutics? Capricor Therapeutics revenue growth between 2023 and 2024 was -12%.
Is Capricor Therapeutics profitable? Yes, Capricor Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.